Main demographic and clinical characteristics of study patients
. | Data . |
---|---|
No. of patients | 1754 |
Age, y, mean ± SD | 66 ± 18 |
Sex, no. M/no. F | 826/928 |
Pregnancy, no. (%) | 32 (1.8) |
Cancer, no. (%) | 268 (15.3) |
Previous heparin exposure, no. (%) | |
More than 3 mo earlier | 538 (30.7) |
Within the previous 3 mo | 60 (3.4) |
Setting of treatment, no. (%) | |
Entirely in the hospital | 816 (46.5) |
Primarily at home | 938 (53.5) |
Indication for LMWH therapy, no. (%) | |
Prevention of VTE | 452 (25.8) |
Treatment of VTE | 530 (30.2) |
Atrial fibrillation | 320 (18.2) |
Coronary artery disease | 187 (10.7) |
Cerebrovascular disease | 108 (6.2) |
Other | 157 (8.9) |
LMWH dosage, no. (%) | |
Fixed low-dose | 376 (21.4) |
Therapeutic adjusted-dose | 728 (41.5) |
Intermediate dose | 650 (37.1) |
LMWH type, no. (%) | |
Nadroparin | 880 (45.6) |
Enoxaparin | 700 (39.9) |
Reviparin | 67 (3.8) |
Dalteparin | 64 (3.6) |
Parnaparin | 43 (2.4) |
LMWH duration, d, median (range) | 8 (2-30) |
. | Data . |
---|---|
No. of patients | 1754 |
Age, y, mean ± SD | 66 ± 18 |
Sex, no. M/no. F | 826/928 |
Pregnancy, no. (%) | 32 (1.8) |
Cancer, no. (%) | 268 (15.3) |
Previous heparin exposure, no. (%) | |
More than 3 mo earlier | 538 (30.7) |
Within the previous 3 mo | 60 (3.4) |
Setting of treatment, no. (%) | |
Entirely in the hospital | 816 (46.5) |
Primarily at home | 938 (53.5) |
Indication for LMWH therapy, no. (%) | |
Prevention of VTE | 452 (25.8) |
Treatment of VTE | 530 (30.2) |
Atrial fibrillation | 320 (18.2) |
Coronary artery disease | 187 (10.7) |
Cerebrovascular disease | 108 (6.2) |
Other | 157 (8.9) |
LMWH dosage, no. (%) | |
Fixed low-dose | 376 (21.4) |
Therapeutic adjusted-dose | 728 (41.5) |
Intermediate dose | 650 (37.1) |
LMWH type, no. (%) | |
Nadroparin | 880 (45.6) |
Enoxaparin | 700 (39.9) |
Reviparin | 67 (3.8) |
Dalteparin | 64 (3.6) |
Parnaparin | 43 (2.4) |
LMWH duration, d, median (range) | 8 (2-30) |